FutureChem Co.,Ltd (220100.KQ)
KRW 18970.0
(0.8%)
KRW 18970.0
(0.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.4 Billion KRW | 34.98% |
| 2022 | -12.93 Billion KRW | -63.81% |
| 2021 | -7.89 Billion KRW | -59.77% |
| 2020 | -4.94 Billion KRW | 12.28% |
| 2019 | -5.63 Billion KRW | 26.66% |
| 2018 | -7.67 Billion KRW | -69.38% |
| 2017 | -4.53 Billion KRW | -16.81% |
| 2016 | -3.88 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.06 Billion KRW | 1.21% |
| 2024 Q2 | -2.69 Billion KRW | -30.21% |
| 2023 FY | -8.4 Billion KRW | 34.98% |
| 2023 Q2 | -2.62 Billion KRW | -43.8% |
| 2023 Q3 | -1.86 Billion KRW | 28.87% |
| 2023 Q4 | -2.09 Billion KRW | -12.18% |
| 2023 Q1 | -1.82 Billion KRW | 65.21% |
| 2022 Q2 | -1.67 Billion KRW | 33.3% |
| 2022 FY | -12.93 Billion KRW | -63.81% |
| 2022 Q4 | -5.24 Billion KRW | -49.46% |
| 2022 Q3 | -3.5 Billion KRW | -109.61% |
| 2022 Q1 | -2.5 Billion KRW | -36.49% |
| 2021 Q3 | -2.1 Billion KRW | 0.0% |
| 2021 Q4 | -1.83 Billion KRW | 12.72% |
| 2021 FY | -7.89 Billion KRW | -59.77% |
| 2020 FY | -4.94 Billion KRW | 12.28% |
| 2019 FY | -5.63 Billion KRW | 26.66% |
| 2018 FY | -7.67 Billion KRW | -69.38% |
| 2017 FY | -4.53 Billion KRW | -16.81% |
| 2016 FY | -3.88 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 56.976% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | 246.858% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 123.309% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 106.84% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 112.573% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 41.433% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 122.535% |
| Boditech Med Inc. | 33.44 Billion KRW | 125.141% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | 209.206% |
| Huons Co., Ltd. | 59.79 Billion KRW | 114.061% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | 177.716% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 48.649% |